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Abstract
Background: Prosthesis-patient mismatch (PPM) is characterised by the effects of inadequate prosthesis size relative to
body surface area (BSA).The purpose of this study was to determine the impact of PPM on late clinical outcomes after
mitral valve replacement (MVR) in rheumatic population.
Methods: From 2000 to 2013, a total of 445 patients (mean age 54.2 ± 11.7 years) underwent isolated MVR (±tricuspid
annuloplasty) for rheumatic disease were investigated. Effective orifice area (EOA) was determined by the continuity
equation and PPM was defined as indexed EOA (EOA/BSA) ≤ 1.2 cm2/m2. Clinical and echocardiographic follow-up
(mean follow up 8.7 ± 4.0 years) results were compared.
Results: 37% of patients (n = 165) had PPM. There were no significant differences in baseline and operative characteristics
between patients with and without PPM except age and IEOA. A significant decrease in mean trans-valvular
pressure gradient (MPG) over time following MVR, however the change of MPG showed no differences between
groups (No PPM vs. PPM: 8.9 ± 4.7 mmHg→ 3.6 ± 1.2 mmHg vs. 8.7 ± 4.5 mmHg→ 3.8 ± 1.4 mmHg, p-value = 0.28).
In all patients, there was a reduction of left atrium dimension (58.6 ± 12.0 mm→ 53.2 ± 12.0 mm vs. 57.9 ± 8.9 mm→
52.2 ± 8.9 mm, p-value = 0.68) and left ventricular end diastolic diameter (49.9 ± 5.7 mm → 48.9 ± 5.7 mm vs. 49.7 ±
6.0 mm → 48.3 ± 5.0 mm, p = 0.24) without statistical significance. Freedom from TR progression rates at 3 and
5 years (99% vs.98%, 99% vs. 98%, p-value = 0.1), and overall survival rates at 3 and 5 years (97% vs. 96%, 94% vs.
94%, p-value = 0.7) were similar.
Conclusion: This study shows that mitral PPM is not associated with atrial /ventricular remodeling and might not
influence late clinical outcome including late TR progression, survival in rheumatic population.
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Background
Previous studies reported that prosthesis–patient mis-
match (PPM) in aortic valve position is strongly associ-
ated with worse hemodynamics, less regression of left
ventricular hypertrophy, more cardiac events, and higher
mortality rates after aortic valve replacement [1–3].
However, PPM following mitral valve replacement (MVR)
has been still less investigated. Previous studies reported
that mitral PPM is various, from 30 to 85% when in vivo
evaluation of effective orifice area (EOA) is performed
[4–6]. Some studies on the clinical impact of PPM fol-
lowing MVR on survival have reported conflicting results,
although two recent trials showed that PPM in the mitral
position independently affects long-term survival.
Dumesnil et al. have addressed that indexed EOA derived
from in vivo postoperative measures is the only parameter
that can consistently be correlated with postoperative gra-
dients as well as clinical outcomes in defining PPM [7].
Mitral PPM can be equated to residual mitral stenosis
* Correspondence: Sak911@yuhs.ac
Division of Thoracic and Cardiovascular Surgery, Severance Cardiovascular
Hospital, Yonsei Cardiovascular Research Institute, Yonsei University, College
of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 03722, Republic of
Korea
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lee et al. Journal of Cardiothoracic Surgery  (2017) 12:88 
DOI 10.1186/s13019-017-0653-x
resulting in increased trans-mitral gradients, increased
left atrial pressure, and pulmonary hypertension (PH).
These factors may lead to right ventricular dilatation/
dysfunction and to atrial fibrillation, which may, in
turn, lead to tricuspid annulus dilatation and functional
tricuspid regurgitation (fTR).
However, despites of small sized mitral prosthesis im-
plantation such as 25 mm, we can easily find that no oc-
currence of TR after MVR during follow duration. In
Asian rheumatic population, mitral annuls size is rela-
tively small compared with western mitral disease, so we
can easily meet the patients with small sized mitral pros-
thesis replacement and collect many cases. The objective
of this study was to investigate the impact of mitral
PPM on late clinical outcomes including TR progression
and survival following MVR in rheumatic population.
Methods
Patient population
We retrospectively reviewed a consecutive series of 445
patients who underwent elective isolated MVR with or
without TAP (tricuspid annuloplasty) for rheumatic mi-
tral valve disease at Severance Cardiovascular Hospital,
University of Yonsei, from Jan 2000 to Dec 2013. Pa-
tients with concomitant aortic valve, coronary artery by-
pass and aorta surgery were excluded. In cases of TAP, if
residual TR grade after TAP were 2,3 and 4, they were
also excluded for minimizing the confusion of TR pro-
gression analysis. Data were retroprospectively collected
and recorded in an electronic database, and clinical
follow-up was completed with routine outpatient clinics.
Patients who did not present at the visit were contacted
by telephone, and all symptoms, mortality, and any com-
plications that occurred during follow-up were recorded.
This study was approved by the Institutional Review
Board of Yonsei University College of Medicine. Individ-
ual patient consent was waived because this study did
not interfere with patient treatment, and the database
was designed so that individual patients could not be
identified. All baseline and clinical characteristics were
obtained from the medical record of patients.
All patients underwent a full median sternotomy and
operation performed on cardio-pulmonary bypass. The
prostheses were used in as followings:
 Mechanical prosthesis: St. Jude Medical Standard
Mechanical (St. Jude Medical Inc., St. Paul, MN)
(n = 140), MIRA (Edwards Lifesciences; Irvine, Calif )
(n = 54), ATS (Medtronic, Minneapolis, MN)
(n = 85), Sorin (Sorin Biomedica, Saluggia, Italy)
(n = 11), ON-X (On-X Life Technology, Austin, TX)
(n = 61), CarboMedics Mechanical (Sulzer
CarboMedics, Austin, TX) (n = 12).
 Bioprosthesis: Perimount Magna (Edwards
Lifesciences LLC, Irvine, CA) (n = 49), Epic
(St. Jude Medical Inc., St. Paul, MN) (n = 17),
Hancock (Medtronic, Minneapolis, MN) (n = 7),
Biocor (St. Jude Medical Inc., St. Paul, MN)
(n = 11). In all cases, posterior chordal preservation
was attempted as a routine maneuver.
Doppler-echocardiographic assessment
Clinical and echocardiographic assessment was performed
prior to MVR and 12–60 months after operation. The
echocardiographic images of the included patients were
reanalyzed by 2 experienced echocardiographers who were
unaware of the patient’s clinical data. LV internal diameter,
septal thickness, and LV posterior wall thickness were
measured at end-diastole. LV mass was calculated using
the formula developed by Devereux et al. [8], and LV mass
was indexed for the body surface area. The left atrial vol-
ume was calculated from the parasternal long-axis view
and apical four-chamber view using the prolate ellipse
method [9]. The severity of TR was assessed using color
flow imaging and regurgitant jet area [10]. Doppler color
flow mapping was used to assess the competency of the
prosthetic valves.
EOA calculation and definition of PPM
The in-vivo prosthetic valve effective orifice area (EOA)
was calculated with the use of the continuity equation,
using the stroke volume measured in the LV outflow
tract divided by the integral of themitral valve transpros-
thetic velocity-time integral during diastole. The indexed
EOA (IEOA) was calculated by dividing the measured
EOA by the patient’s body surface area (BSA) at the time
of follow-up. Indexed EOA was used to define PPM as
significant if ≤ 1.2 cm2/m2, moderate if > 0.9 cm2/m2
and ≤ 1.2 cm2/m2, and severe if ≤ 0.9 cm2/m2 [4].
Statistical analysis
Data were prospectively collected and recorded in an
electronic database; statistical analysis was performed
using the Statistical Package for the Social Sciences,
version 11.0 (SPSS, Chicago, IL). Continuous data are
expressed as the mean and standard deviation; catego-
rical data are expressed as the percentage, comparisons
were made using the 2-sample t and the χ2 or the
Fischer exact tests, respectively. We gain the optimal
cutoff value of IEOA for late TR progression and mor-
tality, receiver operating curve (ROC) method was
used. Comparison between group with or without PPM,
Kaplan Meyer survival analysis was used and p value <
0.05 was considered statistically significant.
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Results
Mitral valve patient–prosthesis mismatch
Of the 445 study patients, PPM was in 165 (37.1%), se-
vere in only 8 by the definition of PPM. The proportion
of patients with PPM was lower in those with mechan-
ical valves (n = 362) than those with bioprosthesis (n =
83) (n = 116, 32% vs. n = 49, 59%, p < 0 .01). An IEOA of
patients with mechanical valves had a higher than those
with bioprosthesis (1.41 ± 0.31 vs. 1.15 ± 0.21, p < 0.01).
The clinical characteristics of the patients are shown in
Table 1. Female portion of patients with PPM were simi-
lar (52, 31.5% vs. 69, 24.6%, p = 0.09) and PMV (Percu-
taneous mitral valvuloplasty) history were also not
significantly different between groups (37, 8.3% vs. 66,
14.8%, p = 0.8). However, the age (55.96 ± 12.36 vs. 53.28
± 10.82, p < 0.01) and BSA (body surface area, m2) in
PPM group (1.61 ± 0.14 vs.1.55 ± 0.15, p < 0.01) was sig-
nificantly higher than no PPM group regardless gender.
Tissue valve portion was meaningfully higher in PPM
group compared with No PPM group (29.7% vs. 12.1%).
Perioperative data and early clinical outcomes
Perioperative and early outcomes including postopera-
tive echocardiography data are shown in Table 2. Thirty-
day mortality was similar between groups (0% vs. 0.2%,
p = 1.0), and postoperative CVA (cerebrovascular acci-
dents) was also not different (0% vs. 0.2%, p = 1.0). There
were also similar rates of other morbidities (postopera-
tive bleeding: 1.8% vs. 1.1%, p = 0.08, acute renal failure:
0.2% vs. 0.7%) between groups.
The mean prosthesis size (mm) in No PPM group was
significantly bigger than PPM group (27.89 ± 1.55 vs.
27.58 ± 1.57, p = 0.03). Values of EOA (2.38 ± 0.41 vs.
1.69 ± 0.15, p < 0.01) and IEOA (1.55 ± 0.25 vs.1.06 ±
0.08, p < 0.01) in No PPM group were also siginificantly
bigger than PPM group (Table 2). The ealry change of
MPG (mmHg) (4.7 ± 4.5 vs.5.3 ± 5.0, p = 0.34) and right
ventricular systolic pressure (RVSP, mmHg) (10.85 ±
14.75 vs.9.91 ± 14.75, p = 0.53) after MVR was similar be-
tween groups.
Late clinical outcomes including postoperative
echocardiography data, TR progression and survival
Mean echocardiography follow up duration was 8.4 ±
3.7 (0.3–15.2) years. Left ventricular ejection fraction
(LVEF, %), left ventricular end systolic dimension
(LVESD, mm), left ventricular end systolic dimension
(LVEDD, mm), left atrim size (anterior-posterior dis-
tance, mm), and mean pressure gradient (MPG, mmHg)
were routinely checked during follow up for analyzing
ventricular remodeling. LVEF improvement in No PPM
group was significantly better than PPM group (Δ: 0.83
± 13.77 vs. 0.98 ± 9.70, p = 0.89). Left atrium (Δ LAD:
11.0 ± 18.8 vs.13.5 ± 19.1, p = 0.19) and ventricular re-
modeling (Δ LVESD: 5.6 ± 12.4 vs. 4.1 ± 11.7, p = 0.2
and Δ LVEDD: 8.3 ± 17.8 vs.5.7 ± 16.0, p = 0.13) were
similar between groups. The reduction of right ven-
tricular systolic pressure (RVSP, mmHg) (8.75 ± 8.2
vs.10.7 ± 17.9 p = 0.30) and the MPG change (4.9 ± 4.5
vs. 5.3 ± 5.0, p = 0.34) were also not siginicantly differ-
ent between groups (Table 3).
Freedom from TR progression (3,4) rate at 3, 5, and
10 years was 99%, 98%, and 93%, respectively. Freedom
from TR progression (3,4) rate in patients with PPM at
3, 5, and 10 years was similar to that of patients without
PPM (98%, 98%, 98% vs. 99%, 99%, 91%, respectively,
P = 0.09) (Fig. 1a). After including TR grade 2, free-
dom from TR progression (2,3,4) in patients with
PPM at 3, 5, and 10 years was similar to that of pa-
tients without PPM (98%, 96%, 94% vs. 98%, 96%,
85%, respectively, P = 0.10) (Fig. 1b).
Table 1 Basic preoperative charateristics
Preoperative parameters
PPM (n = 165) No PPM (n = 280) p value
Age (years) 55.96 ± 12.36 53.28 ± 10.82 0.02
Gender (Female, n, %) 52 (31.5%) 69 (24.6%) 0.09
BSA (cm/m2) 1.61 ± 0.14 1.55 ± 0.15 < 0.01
Valve type (Tissue No, %) 49 (29.7%) 34 (12.1%) < 0.01
Previous PMV Hx. (n, %) 37 (8.3%) 66 (14.8%) 0.82
LVEF (%) 62.70 ± 9.28 60.71 ± 9.52 0.31
LVEDD (mm) 48.27 ± 5.06 48.98 ± 5.72 0.23
LVESD (mm) 32.98 ± 5.17 33.8 ± 6.25 0.19
LAD (AP, mm) 52.29 ± 8.98 53.42 0.38
MPG (mmHg) 8.7 ± 4.52 8.91 ± 4.71 0.38
BSA body surface area, PMV percutaneous mitral valvuloplasty, LVEF left
ventricular ejection fraction, LVEDD left ventricular end diastolic dimension,
LVESD left ventricular end systolic dimension, MPG mean pressure gradient
Table 2 Early clinical outcomes and the the change of
hemodynamics parameters
Perioperative and postoperative parameters
PPM (n = 165) No PPM (n = 280) p value
30 days mortlaity 0 (0%) 1 (0.2%) 1.0
CVA (n, %) 0 (0%) 1 (0.2%) 1.0
ARF (n,%) 1 (0.2%) 3 (0.7%) 1.0
Postoperative Bleeding (n,%) 8 (1.8%) 5 (1.1%) 0.08
Prosthesis size (mm) 27.58 ± 1.57 27.89 ± 1.55 0.03
EOA (cm2) 1.69 ± 0.15 2.38 ± 0.41 < 0.01
IEOA 1.06 ± 0.08 1.55 ± 0.25 < 0.01
The change of RVSP
(mmHg)
10.85 ± 14.75 9.91 ± 14.75 0.53
The change of MPG (mmHg) 4.7 ± 4.5 5.3 ± 5.0 0.34
CVA cerebral vascular event, ARF acute renal failure, EOA effective orifice area,
IEOA indexed effective orifice area, RVSP right ventricular systolic pressure,
MPG mean pressure gradient
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Overall 3, 5, and 10-year survivals were 97%, 94%, and
88%, respectively. Patients with PPM had similar 3, 5,
and 10-year survivals compared with no PPM patients
(96%, 94% and 88% vs. 97%, 94% and 88%, respectively,
P = 0.80) (Fig. 2).
Sub-analysis of severe PPM patients was as followings:
Total eight patients had severe PPM (definition: IEOA ≤
0.9 cm2/m2) and average age was 62.63 years (37 ~ 71).
BSA was 1.7 (1.56 ~ 1.81) and preoperative TR were all
under mild (Gr1). EF was 58.5% (36 ~ 71%), LVEDD was
52.5 mm (47 ~ 59 mm) and LA size (AP diameter, mm)
was 59.3 mm (51 ~ 65 mm). Average IEOA was 0.85
(0.82~0.88). Five were Hancock (n = 2/27 mm, n = 3/
29 mm, Medtronic, Minneapolis, MN), 2 were Epic (n =
2/29 mm, St. Jude Medical Inc., St. Paul, MN) and 1 was
Perimount Magna (n = 1/25 mm, Edwards Lifesciences
LLC, Irvine, CA). There was no in-hospital mortality
and postoperative newly onset TR was none in all cases.
There was just one case of late mortality after postopera-
tive 6 years due to stomach cancer, but this was not cor-
related with cardiac death or TR progression.
For the gaining optimal IEOA cut value of TR progres-
sion, we used ROC method and 1.38 was determined as
a cut value (new PPM value) for TR progression (Fig. 3).
We divided two groups based on 1.38 (IEOA, new PPM)
and compared late TR progression and cumulative sur-
vival. But against our expectation, the larger IEOA group
(1.39 ≤, No PPM) showed inferior tendency of freedom
Table 3 Serial change of hemodynamic characteristic and remodelling data
Preoperative Immediate postoperative Last followup
LVEF (%) No PPM 60.71 60.30 62.09
PPM 61.70 61.60 62.68
LVESD (mm) No PPM 34.64 34.21 33.48
PPM 33.76 33.08 33.09
LVEDD (mm) No PPM 49.92 48.67 48.69
PPM 49.30 47.94 48.06
LAD (AP, mm) No PPM 58.12 51.32 52.62
PPM 57.88 51.03 52.17
MPG (mmHg) No PPM 8.99 3.59 3.76
PPM 8.83 4.01 4.02
RVSP (mmHg) No PPM 42.33 31.82 32.96
PPM 43.75 32.56 33.02
LVEF left ventricular ejection fraction, LVEDD left ventricular end diastolic dimension, LVESD left ventricular end systolic dimension, LAD left atrium dimension, MPG
mean pressure gradient, RVSP right ventricular systolic pressure
Fig. 1 Freedom from TR progression rate at 3, 5, and 10 years between groups (PPM vs. No PPM). a Freedom from TR progression (3,4) rate at 3,
5, and 10 years was 99%, 98%, and 93%, respectively. Freedom from TR progression (3,4) rate in patients with PPM at 3, 5, and 10 years was similar to
that of patients without PPM (98%, 98%, 98% vs. 99%, 99%, 91%, respectively, P = 0.09). b Freedom from TR progression (2,3,4) in patients with PPM at
3, 5, and 10 years was similar to that of patients without PPM (98%, 96%, 94% vs. 98%, 96%, 85%, respectively, P = 0.10)
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from TR progression at 3,5 and 10 years (99, 99% and
88% vs. 99%, 98% and 97%, respectively, P = 0.08)
(Fig. 4a). For survival, Patients with PPM had similar 3,
5, and 10-year survivals compared with no PPM patients
(96%, 92% and 86% vs. 97%, 96% and 89%, respectively,
P = 0.16) (Fig. 4b).
Considering valve type such as mechanical and tissue,
late bleeding event related with warfarin intake showed
higher in mechanical prosthesis group (n = 11, 3.1%)
compared with tissue prosthesis (n = 2, 2.4%) as ex-
pected. Late CVA incidence was 6.3% in mechanical and
10.8% in tissue prosthesis group. Reoperation related
with degeneration was 1.1% in mechanical and 3.6% in
tissue prosthesis group.
Discussion
The main findings of the present study are as followings:
(1) the incidence of PPM after MVR in patients with
Fig. 2 Overall 3, 5, and 10-year survivals were 97%, 94%, and 88%, respectively. Patients with PPM had similar 3, 5, and 10-year survivals compared
with no PPM patients (96%, 94% and 88% vs. 97%, 94% and 88%, respectively, P = 0.80)
Fig. 3 ROC method for the gaining optimal IEOA cut value of TR progression 1.38 was determined as a cut value (new PPM value) for TR progression
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rheumatic mitral stenosis was relatively high against our
expectation; (2) mitral position PPM was not correlated
with late clinical result including late TR progression
and survival; (3) the larger IEOA, the more TR progres-
sion tendency (p = 0.08), ironically.
Since first described in 1978 [11], PPM after MVR has
been suggested to be correlate with poor clinical out-
comes including persistent pulmonary hypertension and
late functional tricuspid regurgitation [2, 12]. Until now,
well descripted mechanism of the adverse effect of PPM
was originated from high residual transvalvular pressure
gradients, which is same with residual mitral stenosis
with similar consequences (ie, the persistence of abnor-
mally high mitral gradients and increased left atrial and
pulmonary arterial pressures). The major consequence
of pulmonary hypertension is right ventricular failure,
which generally results from chronic pressure overload
and associated volume overload with the development of
tricuspid regurgitation. Hence, the persistence of left
atrial and pulmonary hypertension associated with PPM
is likely the main factor responsible for the increased
mortality observed in the patients with severe PPM [4].
However, some reports suggested that PPM did not
affect survival after MVR [13, 14], although several re-
cent trials showed that mitral PPM independently
affects long-term survival [4, 5]. Mitral valve replace-
ment itself should ideally improve pulmonary hyperten-
sion and tricuspid regurgitation without increasing
operative times and risk. The negative effects of aortic
valve PPM on left ventricular remodeling, functional
status, early mortality, and late survival have been ex-
tensively corroborated. [1, 15–17] What remains uncer-
tain is whether clinically deleterious effects of PPM
could be encountered after MVR.
Actually, there has been a recent rising interest in mi-
tral PPM, which has been well documented in the
pediatric population from small BSA and limited size of
prosthesis according to growth potential. A variety of
factors have been used in an attempt to define the con-
cept of clinical PPM in children: These have included
size/weight ratios, Z scores, maximum transprosthesis
velocity (Vmax), and 2.5 times increase in body weight
from the time of implant. In all instances, these factors
have been correlated with outcomes (early mortality,
survival, and PTH) [18, 19]. Adult mitral PPM was the
subject of an original case report in 1981 [20], it has
subsequently been theorized, through in vitro pulse du-
plicator analysis, that an indexed geometrical area
(IGOA) less than 1.3 to 1.5 cm2/m2 could potentially
leave the patient with high postoperative trans-mitral
gradients. In a clinical study, a good correlation between
elevated transprosthetic mitral gradient and in vivo
IEOA was demonstrated by the use of the continuity eq.
(CE) during echocardiographic assessment of porcine
mitral prostheses [7]. In this report, an IEOA of 1.3 to
1.5 cm2/m2 or less at rest was associated with a mean
mitral gradient of 4 mmHg; with every 10% increase in
stroke volume (maximum 50%), there was a proportional
increase of the mean mitral gradient.
However, in our study, there was very weak relation
between trans-mitral gradients and IEOA induced from
correlation coefficient analysis (r = − 0.08, p = 0.07)
(Fig. 5). It means that postoperative decrease of MPG
was induced well regardless of IEOA and there was no
problematic residual pressure gradients which can make
physiologic mitral stenosis (Fig 6a). Also we found that
BSA did not show strong correlation with IOEA (r =
0.27) and PPM incidence was not significantly different
Fig. 4 Freedom from TR progression and overall survival at 3,5 and 10 years. a Freedom from TR progression at 3,5 and 10 years (99, 99% and
88% vs. 99%, 98% and 97%, respectively, P = 0.02). b Freedom from all cause mortality at 3, 5, and 10-year (96%, 92% and 86% vs. 97%, 96% and
89%, respectively, P = 0.16)
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under 29 mm sized population using same correlation
coefficient analysis (r = 0.17) (Fig. 6b). In asian popula-
tion, small size mitral implantation might be considered
generally to be occured more frequently rather than
western population, however implantation prosthesis
size was not so strongly associated with BSA. Mitral
prosthesis size in No PPM group was slightly bigger
than PPM group (27.89 ± 1.55 vs. 27.58 ± 1.57, p = 0.03),
but after exclusion of 31 mm size implanted patients,
there was no significant different between groups
(27.44 ± 1.42 vs. 27.69 ± 1.35, p = 0.08). From the
analysis of TR progression rate, we found contradictory
result that PPM group showed superior freedom from
TR progression rate in both classic IEOA classficaiton
(1.25) and newly gained IEOA (1.38) classification. This
doesn’t necessarily mean that the bigger mitral pros-
thesis, the better clinical outcomes. Bigger mitral im-
plantation might mean two things: 1) Big BSA or 2)
Heart enlargement, however, from our result, big BSA
doesn’t necessarily mean bigger mitral implantation
(Fig. 6a, r = 0.27). Then mitral annulus enlargement
from heart failure might be strong candidate for bigger
Fig. 5 Correlation between trans-mitral gradients and IEOA induced from correlation coefficient analysis (r = − 0.08, p = 0.07)
Fig. 6 Correlation between valve implantation size and BSA, IEOA. a Correlation between valve implantation size and BSA (r = 0.27, p < 0.01).
b Correlation between valve implantation size and IEOA (r = 0.17, p < 0.01)
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prosthesis implantation. Actually mitral annulus enlarge-
ment sometimes closely connected with heart dysfunc-
tion and TR can be more frequently progressed in this
group. Recently published study about mitral PPM sug-
gested mitral PPM significantly affects longterm out-
comes after mitral valve replacement in terms of long-
term survival and freedom from cardiac death [21],
however this study was just analyzed by reference
values and very limited old types of valves.
Study limitations
Our study has limitations that must be recognized. First,
this study was a retrospective study, although all con-
secutive patients who underwent MVR for rheumatic
population during the study period were enrolled. Sec-
ond, this study was limited in rheumatic population in
order to increase the possibility of mitral PPM under hy-
pothesis that rheumatic mitral stenosis actulally showed
small mitral annulus compared with other mitral path-
ologies. Threfore, further evaluation for the extension of
population should be needed.
Conclusions
PPM is not an independent predictor of late onset TR
progression and long term survival rate after MVR.
Hemodynamic positive change and remodeling were
similar regardless of PPM. Also contrary to expectations,
BSA was not so strongly correlated with EOA and the
bigger IEOA showed close correlation with TR progres-
sion tendency. So we suggest that mitral PPM might
have not clinical significance in real world and the most
important thing in MVR is safe implantation by appro-
priate sizing.
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